Sagimet Biosciences Inc. Series A (SGMT)
SGMT · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Signal Snapshot
0
Clinical Trials (ClinicalTrials.gov aggregate)
0
Catalyst Records
3
Publications on Record
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? — Neuro Oncol (2024) PMID 38912846
- Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma. — Clin Cancer Res (2024) PMID 38446982
3 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Sagimet Biosciences Inc. Series A.
Full SGMT Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.